Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Issue 1 (20th January 2017)

• Record Type: Journal Article
• Authors: Mayerle, Julia; Kalthoff, Holger; Reszka, Regina; Kamlage, Beate; Peter, Erik; Schniewind, Bodo; González Maldonado, Sandra; Pilarsky, Christian; Heidecke, Claus-Dieter; Schatz, Philipp; Distler, Marius; Scheiber, Jonas A; Mahajan, Ujjwal M; Weiss, F Ulrich; Grützmann, Robert; Lerch, Markus M
• Is Part Of: Gut. Volume 67:Issue 1(2018)
• Page Start: 128
• Page End: 137
• Publication Date: 2017-01-20
• Subjects: PANCREATIC CANCER -- PANCREATITIS; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2016-312432
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Current non-invasive diagnostic tests can distinguish between pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)) and chronic pancreatitis (CP) in only about two thirds of patients. We have searched for blood-derived metabolite biomarkers for this diagnostic purpose. Design: For a case–control study in three tertiary referral centres, 914 subjects were prospectively recruited with PDAC (n=271), CP (n=282), liver cirrhosis (n=100) or healthy as well as non-pancreatic disease controls (n=261) in three consecutive studies. Metabolomic profiles of plasma and serum samples were generated from 477 metabolites identified by gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. Results: A biomarker signature (nine metabolites and additionally CA19-9) was identified for the differential diagnosis between PDAC and CP. The biomarker signature distinguished PDAC from CP in the training set with an area under the curve (AUC) of 0.96 (95% CI 0.93–0.98). The biomarker signature cut-off of 0.384 at 85% fixed specificity showed a sensitivity of 94.9% (95% CI 87.0%–97.0%). In the test set, an AUC of 0.94 (95% CI 0.91–0.97) and, using the same cut-off, a sensitivity of 89.9% (95% CI 81.0%–95.5%) and a specificity of 91.3% (95% CI 82.8%–96.4%) were achieved, successfully validating the biomarker signature. Conclusions: In patients with CP with an increased risk for pancreatic cancer (cumulative incidence 1.95%), the performance of this biomarker signature results in a negative predictive value of 99.9% (95% CI 99.7%–99.9%) (training set) and 99.8% (95% CI 99.6%–99.9%) (test set). In one third of our patients, the clinical use of this biomarker signature would have improved diagnosis and treatment stratification in comparison to CA19-9.